Illumina Ventures visions is to improve human health by unlocking the power of the genome.
Business Model:
Revenue: $0
Employees: 0-0
Address: 499 Illinois St Ste 210
City: San Francisco
State: CA
Zip: 94158
Country: US
Illumina Ventures is an independently managed venture fund in a strategic partnership with Illumina. Illumina provides the majority of their capital and access to the expertise and vision of the world&s;s leading genomics solutions provider. They invest primarily in early stage companies, in areas where their expertise and special relationship with Illumina can add value. They typically syndicate with other leading institutional and strategic investors. Focus areas include applications of genomics in life science research, healthcare, agriculture and environmental science, public safety and personal wellness.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
9/2019 | Ribometrix | Equity | 7.8M |
10/2015 | 23andMe | Series E | 115M |
1/2021 | Delfi Diagnostics | Series A | 0 |
5/2023 | Pluton Biosciences | Series A | 0 |
1/2016 | Desktop Genetics | Venture Round | - |
11/2021 | Arbor Biotechnologies | Series B | 0 |
11/2017 | NanoCellect Biomedical | Series B | 0 |
12/2022 | Protillion Biosciences | Series A | 0 |
12/2018 | Kallyope | Series B | 21M |
3/2018 | Cernostics | Series A | 2.5M |
6/2019 | Encoded Therapeutics | Series C | 104M |
5/2017 | Genome Medical | Series A | 0 |
1/2018 | Genome Medical | Series A | 11M |
8/2021 | NanoCellect Biomedical | Series D | 0 |
9/2021 | Walking Fish Therapeutics | Series A | 50M |
5/2018 | LunaDNA | Venture Round | 0 |
5/2019 | DNA Script | Series B | 38.5M |
6/2017 | Serimmune | Series A | 8M |
1/2018 | NanoCellect Biomedical | Venture Round | 250k |
9/2021 | Alamar Biosciences | Series B | 80M |
2/2021 | NanoCellect Biomedical | Series C | 0 |
11/2018 | Stilla Technologies | Series A | 18.3M |
5/2019 | LunaDNA | Venture Round | 4.6M |
4/2023 | Pattern Bioscience | Series D | 0 |
9/2022 | LetsGetChecked | Series D | 0 |
3/2022 | Sherlock Biosciences | Series B | 0 |
5/2020 | LetsGetChecked | Series C | 71M |
7/2020 | DNA Script | Series B | 50M |
12/2015 | Kallyope | Series A | 44M |
7/2019 | Cradle Genomics | Series A | 0 |
4/2023 | Pattern Bioscience | Series C | 0 |
3/2020 | Kallyope | Series C | 112M |
1/2020 | Fluent BioSciences | Series A | 0 |
12/2017 | LunaDNA | Seed Round | 2M |
4/2016 | Human Longevity | Series B | 220M |
9/2017 | DNA Script | Series A | 13.2M |
7/2020 | Pattern Bioscience | Series B | 9M |
2/2020 | Stilla Technologies | Series B | 0 |
12/2022 | SonoThera | Series A | 0 |
10/2021 | RedShift BioAnalytics | Series E | 20M |
7/2022 | Delfi Diagnostics | Series B | 0 |
8/2019 | Delfi Diagnostics | Seed Round | 5.5M |
11/2018 | Ribometrix | Series A | 30M |
10/2021 | DNA Script | Series C | 0 |
4/2020 | Actym Therapeutics, Inc. | Series A | 34M |
1/2016 | Twist Bioscience | Series D | 61M |
6/2021 | LetsGetChecked | Series D | 150M |
11/2021 | Stilla Technologies | Debt Financing | 0 |
5/2019 | LunaPBC | Venture Round | 4.6M |
5/2020 | SQZ Biotech | Series D | 0 |
2/2022 | Kallyope | Series D | 0 |
2/2018 | Kallyope | Series B | 66M |
7/2020 | Encoded Therapeutics | Series D | 0 |
8/2018 | SQZ Biotech | Series C | 0 |
8/2021 | Genome Medical | Series C | 0 |
7/2020 | Genome Medical | Series B | 0 |
1/2016 | Biota Technology | Venture Round | - |
11/2020 | Rebus Bio | Series B | 20M |
5/2023 | Pluton Biosciences | Series A | 0 |
4/2023 | Pattern Bioscience | Series C | 0 |
12/2022 | Protillion Biosciences | Series A | 0 |
12/2022 | SonoThera | Series A | 0 |
9/2022 | LetsGetChecked | Series D | 0 |
7/2022 | Delfi Diagnostics | Series B | 0 |
3/2022 | Sherlock Biosciences | Series B | 0 |
2/2022 | Kallyope | Series D | 0 |
11/2021 | Stilla Technologies | Debt Financing | 0 |
11/2021 | Arbor Biotechnologies | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|